New book by Larry Connors Click here Improve your trading - See how
Saturday, October 24: Pre-Conference Panel Discussion
Presenter: Dennis Kim, M.D., Senior Vice President, Medical Affairs
Orexigen Therapeutics
Topic: Pharmacotherapy Update
Time: 1:00 - 3:45 pm ET
Location: Marriott Ballroom Salon 3
Sunday, October 25: Poster Presentations
Embargo Lifts October 25 at 1:00 p.m. ET
Posters Available 1-2pm. and 5-7pm ET
Abstract: 220-P
Presenter: Cheryl Rock, PhD,
University of California La Jolla, San Diego, CA
Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Body Weight
and Improved Metabolic Risk Factors"
Location: Marriott Exhibit Hall
Abstract: 218-P
Presenter: James Hill, PhD, University of Colorado, Denver, CO
Title: "Naltrexone SR/Bupropion SR - Induced Weight Loss is Independent
of Nausea"
Location: Marriott Exhibit Hall
Abstract: 216-P
Presenter: Patrick O'Neil, PhD, Medical University of South Carolina,
Charleston, S.C.
Title: "Early Weight Loss with Naltrexone SR/Bupropion SR Combination
Therapy for Obesity Predicts Long-term Weight Loss"
Location: Marriott Exhibit Hall
Tuesday, October 27: Late-Breaker Presentations
Embargo Lifts October 27 at 11:00 a.m. ET
Presenter: Frank Greenway, M.D., Pennington Biomedical Research Center,
Baton Rouge, LA
Title: "COR-I: A Phase 3 Study Evaluating Two Doses of Naltrexone
SR/Bupropion SR Combination Therapy Showed Significant and Sustained
Weight Loss in Overweight and Obese Subjects"
Time: 11:00 -11:20 a.m. ET
Location: Marriott Ballroom Salon 2
Embargo Lifts October 27 at 11:20 a.m. ET
Presenter: Caroline Apovian, M.D. Boston University Medical Center,
Boston, MA
Title: "Results of the Phase 3, 56-week, COR II Study:
Naltrexone SR/Bupropion SR Combination Therapy Led to Significant and
Sustained Weight Loss in Overweight and Obese Subjects"
Time: 11:20 -11:40 a.m. ET
Location: Marriott Ballroom Salon 2
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave(R), has completed the COR clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
http://www.Orexigen.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.